[8-K] ARS Pharmaceuticals, Inc. Reports Material Event

Rhea-AI Filing Summary

ARS Pharmaceuticals (SPRY) furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company issued a press release attached as Exhibit 99.1 and updated its investor presentation attached as Exhibit 99.2.

Both exhibits are furnished, not filed, under Items 2.02 and 7.01, meaning they are not subject to Section 18 liability and are not incorporated into other filings except by specific reference. SPRY’s common stock trades on The Nasdaq Stock Market LLC.

0001671858false0001671858dei:FormerAddressMember2025-11-102025-11-1000016718582025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 10, 2025

Date of Report (Date of earliest event reported)

ARS Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39756		81-1489190
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

11682 El Camino Real, Suite 300 San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 771-9307

11682 El Camino Real, Suite 120

San Diego, California 92130

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SPRY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 7.01 Regulation FD Disclosure.

On November 10, 2025, the Company updated its corporate presentation for use with investors, analysts and others. The revised presentation is available through the Company’s website, and a copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit Number		Description
99.1		Press Release dated November 10, 2025
99.2		Company Presentation dated November 10, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ARS PHARMACEUTICALS, INC.
Date: November 10, 2025		By:	/s/ Richard Lowenthal
			Richard Lowenthal, M.S., MSEL
			President and Chief Executive Officer
			(Principal Executive Officer)

FAQ

What did ARS Pharmaceuticals (SPRY) disclose in this 8-K?

The company furnished financial results for the quarter ended September 30, 2025 and an updated corporate presentation.

Which exhibits accompany SPRY’s 8-K?

Exhibit 99.1 is the press release dated November 10, 2025; Exhibit 99.2 is the company presentation dated November 10, 2025.

Are the materials considered filed with the SEC?

No. Items 2.02 and 7.01 (including Exhibits 99.1 and 99.2) are furnished, not filed, and not subject to Section 18 liability.

What period do the results cover for SPRY?

The results relate to the quarter ended September 30, 2025.

Where can investors access the updated presentation?

The presentation is available on the company’s website and attached as Exhibit 99.2 to the 8-K.

What is SPRY’s trading venue and ticker?

Common stock trades on The Nasdaq Stock Market LLC under the ticker SPRY.